Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
M.S. Czuczman; A.J. Grillo-López; P. McLaughlin; C.A. White; M. Saleh; L. Gordon; A.F. LoBuglio; J. Rosenberg; B. Alkuzweny; et al. (Profiled Author: Leo I Gordon)
Annals of Oncology. 2001;12(1):109-114.Abstract
Purpose: Patients who were PCR-positive for B-cell leukemia-lymphoma 2 (bel-2) gene rearrangement [t(14;18)] were evaluated for responses to rituximab alone or combined with CHOP. Patients and methods: Patients had relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (IWF: A-D). The single-agent trial used 375 mg/m2 weekly x 4; combination therapy included six cycles of CHOP and six 375 mg/m2 infusions of rituximab. Bcl-2 analyses of bone marrow (BM) and peripheral blood (PB) samples at base-line and following therapy were performed using a PCR assay. Results: In the single-agent trial, of 70 patients whose peripheral blood (PB) was bcl-2 positive at baseline, 36 became bcl-2-negative, 13 remained positive, and 21 varied between positive and negative. The overall response rates (ORRs) were 72%, 31%, and 57%, respectively. Twelve of twenty-two patients with repeat bone marrow (BM) samples were bcl-2-negative three months post-treatment. Of 18 patients in the combination trial, 8 were bcl-2 positive in PB and/or BM. All of seven patients positive in PB at baseline and six of seven patients positive in BM were negative at the end of therapy; all patients responded to treatment (100% ORR). Conclusions: Rituximab, alone or combined with CHOP, eradicated bcl-2 positive cells from PB and BM in over half of the patients treated and was associated with a high overall clinical response rate. The impact on disease-free and overall survival awaits long-term follow up.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Joseph A. Sparano; Jeannette Y. Lee; Lawrence D. Kaplan; Alexandra M. Levine; Juan Carlos Ramos; Richard F. Ambinder; William Wachsman; David Aboulafia; Ariela Noy; David H. Henry; et al.Blood. 2010;115(15):3008-3016.
P. Martin; A. Chadburn; P. Christos; R. Furman; J. Ruan; M.A. Joyce; E. Fusco; P. Glynn; R. Elstrom; R. Niesvizky; et al.Annals of Oncology. 2008;19(7):1327-1330.
Y. Kaneko; R.A. Larson; D. Variakojis; J.M. Haren; J.D. RowleyBlood. 1982;60(4):877-887.
Appears in this Document